Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | CHKA | P35790 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731327 | 0.79 | CA9 (0.58) | PTGS1PTGS2CA1CA2CA9 | |
| SCHEMBL1689504 | 0.76 | SMO (0.45) | CHKAALDH1A1TNIKMAP4K1DRD2 | |
| SCHEMBL2905339 | 0.74 | ALDH1A1 (0.53) | ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL7261049 | 0.73 | CHKA (0.50) | CHKAALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL2761085 | 0.72 | DHODH (0.43) | ALDH1A1TNIKMAP4K1DRD2DRD4 | |
| SCHEMBL5737789 | 0.71 | SMO (0.44) | ALDH1A1TNIKDRD2DRD4DRD3 | |
| SCHEMBL7256544 | 0.70 | DRD4 (0.44) | CHKAALDH1A1MAP4K1DRD2DRD4 | |
| SCHEMBL5224217 | 0.69 | SMO (0.44) | ALDH1A1MAP4K1DRD2DRD4DRD3 | |
| SCHEMBL5225912 | 0.69 | MAP4K1 (0.41) | CHKAALDH1A1MAP4K1DRD2DRD4 | |
| SCHEMBL5228638 | 0.69 | DRD4 (0.41) | ALDH1A1MAP4K1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KCNH2 353/4885CHKA 3448/4885ALOX5 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.